Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 1 | 3 |
| 1995 | 0 | 1 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 1 | 1 |
| 2005 | 3 | 3 | 6 |
| 2006 | 4 | 6 | 10 |
| 2007 | 2 | 4 | 6 |
| 2008 | 2 | 5 | 7 |
| 2009 | 11 | 7 | 18 |
| 2010 | 9 | 9 | 18 |
| 2011 | 5 | 8 | 13 |
| 2012 | 5 | 5 | 10 |
| 2013 | 8 | 9 | 17 |
| 2014 | 7 | 6 | 13 |
| 2015 | 6 | 3 | 9 |
| 2016 | 8 | 3 | 11 |
| 2017 | 8 | 3 | 11 |
| 2018 | 9 | 3 | 12 |
| 2019 | 12 | 8 | 20 |
| 2020 | 5 | 4 | 9 |
| 2021 | 7 | 6 | 13 |
| 2022 | 2 | 1 | 3 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer. Mol Cancer Ther. 2023 02 01; 22(2):192-204.
-
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer. Expert Opin Drug Discov. 2023 01; 18(1):65-81.
-
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in?vitro and in?vivo. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2201073119.
-
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022 06 01; 28(11):2270-2277.
-
A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433.
-
Tofacitinib Ameliorates Retinal Vascular Leakage in a Murine Model of Diabetic Retinopathy with Type 2 Diabetes. Int J Mol Sci. 2021 Nov 02; 22(21).
-
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
-
Targeted Therapy for BRAF Mutant Brain Tumors. Curr Treat Options Oncol. 2021 10 06; 22(11):105.
-
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nat Commun. 2021 09 09; 12(1):5337.
-
Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases. Breast Cancer Res. 2021 07 27; 23(1):76.